During the last year, several fast-spreading SARS-CoV-2 virus variants have emerged due to various mutations. The most important mutations are located in the Spike S1 RBD protein domain and some of the identified mutations in the RBD domain occur in more than one strain. These mutations are far more dangerous than the original wild-type virus: they lead to a significantly higher transmissibility of COVID-19 and can also dramatically affect the effectiveness of existing vaccines. Therefore, these variants pose even greater challenges not only to the scientific world.
Since the outbreak of the COVID-19 Pandemic in January 2020, the World Health Organization (WHO), in collaboration with partners, institutes and experts have been monitoring and assessing the evolution of SARS-CoV-2. In order to prioritise global surveillance and research, and ultimately inform the ongoing response to the COVID-19 pandemic, WHO has published a list of specific SARS-CoV-2 variants of interest (VOIs) and variants of concern (VOCs).
To support the scientific community to fight against the ongoing COVID-19 pandemic, trenzyme offers a wide range of recombinant SARS-CoV-2 Variants, including the important VOCs and several VOIs, which can be used to evaluate the efficacy of the antibodies, vaccines and even diagnostic tests.